Provider of immunoassay kits, antibodies, and reagents to the life sciences and translational research markets, has appointed Dan Calvo as president and chief executive officer
Prior to joining ADI, Calvo was president and CEO of Cellomics in Pittsburgh, PA, a provider of high content cellular screening platforms, which was acquired by Fisher Scientific International (now Thermo Fisher Scientific) in August 2005.
Calvo has also served as vice president of worldwide sales and service for PerkinElmer Life and Analytical Sciences, and senior vice president of Nen Life Sciences, which was acquired by PerkinElmer in 2000.
"I am delighted about the opportunity to lead Assay Designs as it enters an expansion phase", commented Calvo.
"ADI has high quality products, strong development capabilities and well-established brands in the life sciences research community.
"By leveraging these strengths and accelerating the addition of new products via internal development and external partnerships, we will strengthen our position as a preeminent, global supplier of innovative reagents and assays".
David Parker, chairman of Assay Designs and a general partner at Ampersand Ventures, stated: "Dan has a proven track record in the research products sector.
"His experience leading the transformation of Cellomics from an entrepreneurial, technology venture into a high growth, professionally-run business and building meaningful stakeholder value in the process is particularly relevant to ADI.
"His energy, leadership, strategic bandwidth and operational strength will serve to evolve ADI into a top-tier life sciences tools company."
